IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$75.76 USD
+2.15 (2.92%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $75.48 -0.28 (-0.37%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
ITCI 75.76 +2.15(2.92%)
Will ITCI be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ITCI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ITCI
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
RVTY's Latest Launch to Enable APOE Genotyping of Alzheimer's Disease
ITCI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?
Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
Other News for ITCI
Intra-Cellular Therapies Inc (ITCI) Shares Up 3.21% on Oct 11
Intra-Cellular price target raised by $3 at Morgan Stanley, here's why
Intra-Cellular Therapies (ITCI) Gets a Buy from Morgan Stanley
JPMorgan Chase & Co's Strategic Acquisition of Shares in Intra-Cellular Therapies Inc
Intra-Cellular Therapies Breaks Below 200-Day Moving Average - Notable for ITCI